Posts By: pharmanewsdaily

3M to sell drug delivery business to Altaris Capital for $650m

US industrial conglomerate 3M has signed a cash-cum-stock deal worth around $650 million to sell substantially all of its drug delivery business to an affiliate of Altaris Capital Partners for about $650 million, as per the latest pharma acquisition news. As per the terms of the deal, the total consideration includes cash, an interest-bearing security, […]

Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) in patients who are treatment-naïve. The US pharma company is aiming to enroll 400 patients in the late-stage clinical trial. The patients will be grouped randomly to be subjected to […]

Leucadia launches Sodium Tetradecyl Sulfate injection for varicose veins

Leucadia Pharmaceuticals, the commercial sales unit of Custopharm, has launched the FDA-approved Sodium Tetradecyl Sulfate (STS) generic injection in the US. According to Leucadia Pharmaceuticals, the regulated sclerosing agent is therapeutically equivalent to SOTRADECOL and is an effective and safe alternative to the use of unapproved compounded products. Sodium Tetradecyl Sulfate is used for the […]

AbbVie, Scripps Research to collaborate on developing new therapeutics

US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for a variety of diseases, including in the therapeutic areas of oncology, immunology, fibrosis, and neurology. Peter Schultz – CEO of Scripps Research and Calibr, its drug discovery unit, said: “Based […]

GE Healthcare, ASLS form R&D partnership to advance 3D biofabrication

GE Healthcare Life Sciences has joined forces with Advanced Solutions Life Sciences (ASLS) for an R&D and distribution partnership with a goal to create new opportunities for regenerative tissue manufacturing by advancing the field of 3D biofabrication. The companies said that the integration of IN Cell Analyzer and BioAssemblyBot systems technologies will embed cellular-level evaluations […]

Astellas Pharma to acquire US gene therapy company Audentes Therapeutics

Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition news. Based in California, Audentes Therapeutics calls itself a clinical-stage company focused on developing a portfolio of Adeno-associated virus (AAV)-based genetic medicines for the […]

Janssen to acquire skin disease drug candidate bermekimab from XBiotech

Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational compound for certain skin disorders, from XBiotech, in a deal worth up to $1.35 billion, as per the latest pharma acquisition news. Bermekimab, which is an anti-IL-1alpha monoclonal antibody (mAb), […]

Precision oncology company Black Diamond Therapeutics raises $85m

Black Diamond Therapeutics, a precision oncology company based in Cambridge, has raised $85 million from a Series C financing round led by Boxer Capital of the Tavistock Group. Additional new investors in the Series C round included Wellington Management Company, BVF Partners, Deerfield Management, funds managed by Janus Henderson Investors, Logos Capital, and Casdin Capital. […]

AstraZeneca taps into Gatehouse Bio’s sRNAlytics AI platform for drug discovery

US biodata company Gatehouse Bio is joining forces with pharma giant AstraZeneca to accelerate the discovery of new drugs for respiratory and cardiovascular diseases using sRNAlytics, the former’s artificial intelligence (AI)-driven platform. According to Gatehouse Bio, the sRNAlytics platform is capable of identifying new small RNA (sRNA) signatures and can illuminate molecular pathways correlated to […]

Soligenix all set to begin FLASH clinical trial for SGX301 in CTCL

US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 (synthetic hypericin) in cutaneous T-cell lymphoma (CTCL). The late-stage study enrolled 169 subjects in the FLASH clinical trial. This was after Soligenix secured positive interim analysis, which included a prospectively […]

Scroll To Top